Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE 2: Secukinumab in Active Psoriatic Arthritis
NCT01752634Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2013
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriatic arthritis (PsA) (4 arms), sponsored by Novartis. Primary endpoint: American College of Rheumatology 20 Response at 24 weeks. Started Apr 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01752634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01752634.